Back to top

Image: Shutterstock

HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?

Read MoreHide Full Article

Key Takeaways

  • Halozyme shares have gained 43.1% in six months, outperforming the industry, sector and S&P 500.
  • Halozyme's royalty revenues jumped 45.8% to $889.4 million in the first nine months of 2026.
  • New technology deals and proprietary product growth aid expansion, but partner reliance remains a risk.

Shares of Halozyme Therapeutics (HALO - Free Report) have witnessed steady growth in the past six months, driven by growing investor confidence surrounding the company’s novel drug delivery technology, ENHANZE, for the subcutaneous (SC) administration of drugs. The stock has rallied 43.1% over the past six months, while the industry has increased 12.4%. HALO shares have also outperformed the sector and the S&P 500 in this timeframe, as seen in the chart below.

HALO Stock Outperforms Industry, Sector & S&P 500

Zacks Investment Research
Image Source: Zacks Investment Research

Halozyme has collaboration agreements with large pharma companies that use its ENHANZE technology for the development of SC formulations of their various approved drugs. Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.

The company has several marketed partnered drugs based on this technology, including the SC formulation of J&J’s (JNJ - Free Report) Darzalex, argenx’s (ARGX - Free Report) Vyvgart Hytrulo as well as Roche’s (RHHBY - Free Report) Phesgo.

Let’s analyze Halozyme’s strengths and weaknesses to understand how to play the stock amid the recent price rally.

HALO Thrives on ENHANZE Technology

Halozyme’s top line is being driven by higher royalty payments from J&J for SC Darzalex, argenx for Vyvgart Hytrulo, and Roche for Phesgo, among other products. Total revenues rose 43% year over year to $1.35 billion in the first nine months of 2026.

Revenues from royalties rose 45.8% year over year to $889.4 million during the first nine months of 2026. Royalties accounted for approximately 66% of Halozyme’s total revenues during this period.

Management expects total revenues to continue to rise on increased royalty revenues from partners and higher product sales heading into 2027.

Reflecting the strength of its overall business performance, Halozyme raised its total revenue guidance for 2026 when it reported better-than-expected third-quarter 2026 results earlier this month.

The company raised its total revenue guidance to $1.86-$1.925 billion, indicating a year-over-year growth of 33-38%. HALO also raised its royalty revenue guidance to $1.24-$1.26 billion from the previous range of $1.22-$1.24 billion. The updated outlook implies year-over-year growth of 42-45%.

Continued sales growth of established ENHANZE-enabled products is expected to support the company's royalty stream. However, Halozyme’s heavy reliance on partners for income through royalties and collaborations remains an overhang. In addition, many of its partnered products face strong competition in the United States, including from biosimilars.

HALO’s Other Key Activities

The 2022 acquisition of Antares Pharma added an industry-leading auto-injector platform that complements Halozyme’s ENHANZE technology. Halozyme added two proprietary products, Xyosted and Hylenex, to its portfolio through this acquisition.

Incremental sales from these products have been boosting Halozyme’s top line. Total product sales increased 56.6% year over year to $397.4 million in the first nine months of 2026. Management now expects product sales of $525-$540 million for 2026.

Halozyme recently acquired Elektrofi and Surf Bio to broaden its drug-delivery technology portfolio and support the development of partner products. Through these acquisitions, the company added Elektrofi’s ultra-high-concentration microparticle technology, Hypercon, and Surf Bio’s hyperconcentration technology, Aerocon. Both technologies complement ENHANZE by enabling the development and delivery of highly concentrated biologics.

These additions are expected to support Halozyme’s long-term growth prospects by creating further opportunities for licensing and royalty revenues.

HALO’s Valuation & Estimate Revisions

From a valuation standpoint, Halozyme is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the stock currently trades at 6.56 times trailing 12-month sales, higher than 2.65 times for the industry. The stock is trading below its five-year mean of 7.17.

Zacks Investment Research
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased from $8.73 to $8.84 over the past 60 days. During the same time frame, EPS estimates for 2027 have moved up from $9.80 to $10.30.

Zacks Investment Research
Image Source: Zacks Investment Research

How to Play HALO Stock

We would suggest holding on to this Zacks Rank #3 (Hold) stock for now. Though it is trading at a premium compared to the industry, the recent price rally, supported by its strong performance in the first nine months of 2026 and upbeat full-year guidance, is likely to keep investors optimistic.

Royalties from partners should continue to boost the top line, while incremental contributions from its proprietary products should aid revenues heading into 2027. Rising estimates also reflect analysts' improving outlook for the stock.

Halozyme’s recent deals to diversify its drug delivery technology offerings provide long-term growth visibility. The company is also focused on signing new collaboration deals for ENHANZE technology. However, heavy dependence on partners for revenues through royalties remains a concern.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in